The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback